Pharmacyclics, Inc. - PCYC - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 12, 2013

Pharmacyclics, Inc. - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
PCYC	Nasdaq	8731	http://www.pcyc.com/index.html	84.89 +0.97
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Pharmacyclics, Inc. Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care Innovation - May 16th, 2013 11:23 am PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - May 15th, 2013 9:02 pm With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What - May 15th, 2013 5:09 pm ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up - May 15th, 2013 4:00 pm ASCO '13 Preview: Gilead's Big Cancer Debut - May 15th, 2013 4:00 pm Three Value-Presenting Stocks With Upgrades on Monday - May 15th, 2013 10:24 am PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a Vote of - May 14th, 2013 9:02 pm Pharmacyclics Rises On Unusually High Volume (PCYC) - May 13th, 2013 1:53 pm 3 Biotech Stocks Spiking With Big Volume - May 13th, 2013 1:06 pm 6 Superstars For Your Biotech Portfolio: John McCamant - May 10th, 2013 12:57 pm Climbing the Wall of Worry - May 10th, 2013 9:44 am Right Time To Buy This Pharmaceutical Company? - May 7th, 2013 11:58 am PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report - May 7th, 2013 8:14 am 2 Winners and 3 Losers from This Week’s Earnings Storm - May 4th, 2013 2:43 pm Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential - May 3rd, 2013 8:18 pm Wider-Than-Expected Loss at Pharmacyclics - May 2nd, 2013 11:30 am David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co., Interviews with The Wall Street Transcript: Alternative Dosage Forms Create Barriers Against Competition in Generics - May 2nd, 2013 9:08 am Pharmacyclics Management Discusses Q1 2013 Results - Earnings Call Transcript - May 1st, 2013 7:40 pm Pharmacyclics Earnings: Everything You Must Know Now - May 1st, 2013 5:37 pm Pharmacyclics posts bigger 1Q loss on stock costs - May 1st, 2013 4:37 pm View All Current Headlines >>